This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
by Zacks Equity Research
Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.
SMMTNegative Net Change GSKPositive Net Change RCUSNegative Net Change
biotechs
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results?
by Ahan Chakraborty
LLY's blockbuster GLP-1 portfolio takes center stage as investors watch Mounjaro, Zepbound and Foundayo for clues to Q2 growth and outlook.
LLYPositive Net Change NVOPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will AbbVie's Oncology Franchise Remain Under Pressure in Q2?
by Sundeep Ganoria
ABBV's Q2 oncology revenues may edge lower as Imbruvica weakness outweighs gains from Venclexta and newer cancer therapies.
ABBVNegative Net Change AZNPositive Net Change PFEPositive Net Change MRKNegative Net Change
biotechs earnings medical pharmaceuticals
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
by Zacks Equity Research
Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.
AGIOPositive Net Change NBIXPositive Net Change AMRNPositive Net Change LQDANegative Net Change
biotechs medical
NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters Now
by Zacks Equity Research
Novo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical data changes the comparison as the GLP-1 rivalry intensifies.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?
by Sundeep Ganoria
Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.
SRPTPositive Net Change DYNPositive Net Change WVEPositive Net Change RGNXNegative Net Change
biotechs gene-editing gene-therapy medical
Here's Why You Should Add Savara Stock to Your Portfolio Now
by Zacks Equity Research
SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.
SVRANegative Net Change NBIXPositive Net Change AMRNPositive Net Change LQDANegative Net Change
biotechs medical
Can LQDA's Differentiated PAH Strategy Drive Long-Term Growth?
by Ekta Bagri
Liquidia's Yutrepia is driving strong growth with rapid commercial adoption as the company expands its pipeline and competes in the evolving PAH market.
LQDANegative Net Change JNJPositive Net Change UTHRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Why CELC Stock Declined 15% in a Week Despite a Major FDA Win
by Zacks Equity Research
Celcuity slides 15% despite FDA approval of Revtorpyk as investors focus on a late Q3 2026 launch that delays commercial sales and near-term revenues.
CELCNegative Net Change AZNPositive Net Change NVSPositive Net Change PFEPositive Net Change
biotechs medical pharmaceuticals
Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well
by Zacks Equity Research
Novartis tops Q2 earnings and revenue estimates as growth from key brands offsets generic pressure, while reaffirming 2026 guidance and advancing acquisitions.
NVSPositive Net Change RHHBYPositive Net Change NVAXPositive Net Change LQDANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals